Recruiting

Testing a new engineered immune cell treatment for advanced blood cancer

Plain-English translation of NCT06132711 on ClinicalTrials.gov ↗ · Source last updated November 2023 · Translation generated June 2026 · How we translate trials

Read our Multiple Myeloma research guide →

Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.

What is this trial?

This trial is testing a new immunotherapy called APRIL-BAFF-Bicephali CAR-T cells for people whose multiple myeloma (a blood cancer) has stopped responding to other treatments. Researchers will collect some of your immune cells, engineer them in the laboratory to better fight cancer, and then put them back into your body. The goal is to see if this treatment is safe and effective at controlling your disease.

Multiple myeloma can become resistant to standard treatments, leaving patients with few options and poor outcomes. This trial exists to test whether this new engineered cell therapy can help patients whose cancer has stopped responding to available treatments.

Do you qualify?

You likely qualify if…

you are between 18 and 70 years old
you have been diagnosed with multiple myeloma that has come back or stopped responding to previous treatments
you are expected to live at least 12 weeks
you have healthy enough heart, liver, and kidney function to tolerate the treatment
you are either not a candidate for stem cell transplant or have decided against it
you understand the trial and are willing to sign a consent form

You likely don't qualify if…

you are pregnant, breastfeeding, or planning to become pregnant in the next six months
you have an active infection like HIV, tuberculosis, hepatitis B, or hepatitis C
you have a severe autoimmune disease or a history of severe allergies
you have an active serious infection requiring treatment
you are unable to cooperate with medical exams or have untreated mental health conditions

What participation looks like

You will first undergo screening tests to make sure you qualify. Then doctors will collect white blood cells from you through a special blood collection procedure called apheresis (this takes several hours). While your cells are being engineered in the laboratory over several weeks, you will receive chemotherapy to prepare your body. Once your engineered cells are ready, you will be admitted to the hospital to receive the cell infusion. After that, you will have frequent check-ins for safety and effectiveness monitoring — weekly visits for one month, then monthly for six months, then every three months.

AI-generated summary from trial data · Jun 4, 2026 · Not medical advice

Trial locations(1 site)

China

Kailin Xu, Xuzhou, Jiangsu